MedTrace Logo

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

NCT00100568 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-09-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of the anti-HIV drugs efavirenz and lamivudine/zidovudine given to treatment-naive HIV-infected people in Dakar, Senegal.

Conditions

  • HIV Infections

Interventions

DRUG

Efavirenz

600 mg tablet taken orally daily

DRUG

Lamivudine/zidovudine

150mg lamivudine/300mg zidovudine tablet taken orally twice daily

Sponsors & Collaborators

  • Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV)

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Souleymane Mboup, PharmD · Laboratoire de Bacteriologic et de Virologie, Hospital Le Dantec Avenue Pasteur

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Senegal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100568 on ClinicalTrials.gov